These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
893 related articles for article (PubMed ID: 15671528)
1. Vaccination of dendritic cells loaded with interleukin-12-secreting cancer cells augments in vivo antitumor immunity: characteristics of syngeneic and allogeneic antigen-presenting cell cancer hybrid cells. Suzuki T; Fukuhara T; Tanaka M; Nakamura A; Akiyama K; Sakakibara T; Koinuma D; Kikuchi T; Tazawa R; Maemondo M; Hagiwara K; Saijo Y; Nukiwa T Clin Cancer Res; 2005 Jan; 11(1):58-66. PubMed ID: 15671528 [TBL] [Abstract][Full Text] [Related]
2. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen. Ojima T; Iwahashi M; Nakamura M; Matsuda K; Naka T; Nakamori M; Ueda K; Ishida K; Yamaue H Int J Oncol; 2006 Apr; 28(4):947-53. PubMed ID: 16525645 [TBL] [Abstract][Full Text] [Related]
3. Strategies for antigen choice and priming of dendritic cells influence the polarization and efficacy of antitumor T-cell responses in dendritic cell-based cancer vaccination. Galea-Lauri J; Wells JW; Darling D; Harrison P; Farzaneh F Cancer Immunol Immunother; 2004 Nov; 53(11):963-77. PubMed ID: 15146294 [TBL] [Abstract][Full Text] [Related]
4. [Allogeneic dendritic cell vaccine pulsed with heat shocked tumor cell lysate can enhance antitumor immunity]. You J; Wang CL; Hao XS Zhonghua Yi Xue Za Zhi; 2007 Oct; 87(39):2785-90. PubMed ID: 18167273 [TBL] [Abstract][Full Text] [Related]
5. Dendritic cell-tumor cell hybrids enhance the induction of cytotoxic T lymphocytes against murine colon cancer: a comparative analysis of antigen loading methods for the vaccination of immunotherapeutic dendritic cells. Yasuda T; Kamigaki T; Nakamura T; Imanishi T; Hayashi S; Kawasaki K; Takase S; Ajiki T; Kuroda Y Oncol Rep; 2006 Dec; 16(6):1317-24. PubMed ID: 17089056 [TBL] [Abstract][Full Text] [Related]
6. Dendritic cells fused with allogeneic colorectal cancer cell line present multiple colorectal cancer-specific antigens and induce antitumor immunity against autologous tumor cells. Koido S; Hara E; Homma S; Torii A; Toyama Y; Kawahara H; Watanabe M; Yanaga K; Fujise K; Tajiri H; Gong J; Toda G Clin Cancer Res; 2005 Nov; 11(21):7891-900. PubMed ID: 16278414 [TBL] [Abstract][Full Text] [Related]
7. Dendritic cell activation by combined exposure to anti-CD40 plus interleukin (IL)-12 and IL-18 efficiently stimulates anti-tumor immunity. Balkow S; Loser K; Krummen M; Higuchi T; Rothoeft T; Apelt J; Tuettenberg A; Weishaupt C; Beissert S; Grabbe S Exp Dermatol; 2009 Jan; 18(1):78-87. PubMed ID: 19054060 [TBL] [Abstract][Full Text] [Related]
8. Polarization of naive T cells into Th1 or Th2 by distinct cytokine-driven murine dendritic cell populations: implications for immunotherapy. Feili-Hariri M; Falkner DH; Morel PA J Leukoc Biol; 2005 Sep; 78(3):656-64. PubMed ID: 15961574 [TBL] [Abstract][Full Text] [Related]
9. Eliciting T cell immunity against poorly immunogenic tumors by immunization with dendritic cell-tumor fusion vaccines. Wang J; Saffold S; Cao X; Krauss J; Chen W J Immunol; 1998 Nov; 161(10):5516-24. PubMed ID: 9820528 [TBL] [Abstract][Full Text] [Related]
10. Local secretion of IL-12 augments the therapeutic impact of dendritic cell-tumor cell fusion vaccination. Tan C; Dannull J; Nair SK; Ding E; Tyler DS; Pruitt SK; Lee WT J Surg Res; 2013 Dec; 185(2):904-11. PubMed ID: 23891424 [TBL] [Abstract][Full Text] [Related]
11. [Induction of Th1 immune response against tumor by genetically engineered fusion of tumor cells and dendritic cells]. Zhang W; Yang H; Zeng H; Chen Z Zhonghua Xue Ye Xue Za Zhi; 2002 Feb; 23(2):61-4. PubMed ID: 12015071 [TBL] [Abstract][Full Text] [Related]
12. Dendritic cells engineered to express the Flt3 ligand stimulate type I immune response, and induce enhanced cytoxic T and natural killer cell cytotoxicities and antitumor immunity. Liu Y; Huang H; Chen Z; Zong L; Xiang J J Gene Med; 2003 Aug; 5(8):668-80. PubMed ID: 12898636 [TBL] [Abstract][Full Text] [Related]
13. [Therapeutic effects of treatment of pancreatic carcinoma by interleukin-23 and apoptotic cell antigen-modified dendritic cell vaccine: experiment with mice]. Tan G; Wang ZY; Yin S Zhonghua Yi Xue Za Zhi; 2006 Apr; 86(14):943-6. PubMed ID: 16759530 [TBL] [Abstract][Full Text] [Related]
14. Enhanced antitumor immunity derived from a novel vaccine of fusion hybrid between dendritic and engineered myeloma cells. Hao S; Bi X; Xu S; Wei Y; Wu X; Guo X; Carlsen S; Xiang J Exp Oncol; 2004 Dec; 26(4):300-6. PubMed ID: 15627063 [TBL] [Abstract][Full Text] [Related]
15. Administration of interleukin-12 enhances the therapeutic efficacy of dendritic cell-based tumor vaccines in mouse hepatocellular carcinoma. Tatsumi T; Takehara T; Kanto T; Miyagi T; Kuzushita N; Sugimoto Y; Jinushi M; Kasahara A; Sasaki Y; Hori M; Hayashi N Cancer Res; 2001 Oct; 61(20):7563-7. PubMed ID: 11606395 [TBL] [Abstract][Full Text] [Related]
16. Enhancement of anti-tumor immunity by high levels of Th1 and Th17 with a combination of dendritic cell fusion hybrids and regulatory T cell depletion in pancreatic cancer. Yamamoto M; Kamigaki T; Yamashita K; Hori Y; Hasegawa H; Kuroda D; Moriyama H; Nagata M; Ku Y; Kuroda Y Oncol Rep; 2009 Aug; 22(2):337-43. PubMed ID: 19578774 [TBL] [Abstract][Full Text] [Related]
17. Engineered fusion hybrid vaccine of IL-18 gene-modified tumor cells and dendritic cells induces enhanced antitumor immunity. Xia D; Li F; Xiang J Cancer Biother Radiopharm; 2004 Jun; 19(3):322-30. PubMed ID: 15285878 [TBL] [Abstract][Full Text] [Related]
18. Interleukin 18 transfection enhances antitumor immunity induced by dendritic cell-tumor cell conjugates. Ju DW; Tao Q; Lou G; Bai M; He L; Yang Y; Cao X Cancer Res; 2001 May; 61(9):3735-40. PubMed ID: 11325846 [TBL] [Abstract][Full Text] [Related]
19. Murine dendritic cells pulsed with an anti-idiotype antibody induce antigen-specific protective antitumor immunity. Saha A; Chatterjee SK; Foon KA; Primus FJ; Bhattacharya-Chatterjee M Cancer Res; 2003 Jun; 63(11):2844-54. PubMed ID: 12782590 [TBL] [Abstract][Full Text] [Related]
20. Expression of toll-like receptor 4 on dendritic cells is significant for anticancer effect of dendritic cell-based immunotherapy in combination with an active component of OK-432, a streptococcal preparation. Okamoto M; Furuichi S; Nishioka Y; Oshikawa T; Tano T; Ahmed SU; Takeda K; Akira S; Ryoma Y; Moriya Y; Saito M; Sone S; Sato M Cancer Res; 2004 Aug; 64(15):5461-70. PubMed ID: 15289356 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]